Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
The Laryngoscope C 2013 The American Laryngological, V Rhinological and Otological Society, Inc. Systematic Review GJB2-Associated Hearing Loss: Systematic Review of Worldwide Prevalence, Genotype, and Auditory Phenotype Dylan K. Chan, MD, PhD; Kay W. Chang, MD Objectives/Hypothesis: To perform a systematic review of GJB2-associated hearing loss to describe genotype distributions and auditory phenotype. Data Sources: 230 primary studies identified from Pubmed. Review Methods: Pubmed was searched systematically to screen broadly for any study reporting on genotype and carrier frequencies for biallelic GJB2-associated hearing loss in defined populations around the world. Genotype and audiometric data were extracted and subjected to meta-analysis to determine genotype distributions, carrier frequencies, rates of asymmetric or progressive hearing loss, and imaging abnormalities. Results: A total of 216 articles comprising over 43,000 hearing-loss probands were included. The prevalence of biallelic GJB2-associated hearing loss was consistent across most of the 63 countries examined, with different mutations being predominant in different countries. Common mutations were found in greater than 3% of the general population worldwide. Meta-analysis of 48 case-control studies demonstrated a two-fold higher carrier frequency among hearing-impaired individuals compared to normal-hearing controls for truncating alleles, but not V37I. Progression, asymmetry, and imaging abnormalities were present in 14% to 19% of individuals with GJB2-associated hearing loss. Conclusion: GJB2 mutations are highly prevalent around the world. The multiple predominant mutations present in different populations attest to the importance of this gene for normal cochlear function and suggests an evolutionary heterozygote advantage. The unusually high carrier rate for truncating mutations among hearing-impaired individuals is consistent with either the presence of complementary mutations or a carrier phenotype. The significant rate of asymmetry and progression highlights the importance of diagnostic workup and close follow-up for this highly variable condition. Key Words: Hearing loss, connexin 26, genetics. Laryngoscope, 124:E34–E53, 2014 INTRODUCTION Hearing loss is the most common congenital sensory impairment, affecting one in 500 newborns and one in 300 children by the age of 4.1 The most frequent genetic cause of congenital sensorineural hearing loss (SNHL) is disruption of GJB2, the gene encoding Connexin 26 (Cx26), the major component of gap junctions in the cochlea. Ever since the first description of GJB2associated hearing loss in 1997,2 mutations have been described in many different populations around the world, with specific genotypes segregating with particular ethnic populations.3 As complete DNA sequencing of From the Department of Otolaryngology-Head and Neck Surgery (D.K.C.), University of California, San Francisco; and the Department of Otolaryngology-Head and Neck Surgery (K.W.C.), Stanford University School of Medicine, Stanford, California, U.S.A Send correspondence to Dylan K. Chan, MD, PhD, Pediatric Otolaryngology, 2233 Post Street, 3rd Floor, Box 1225, San Francisco, CA 94115. E-mail: [email protected] Editor’s Note: This Manuscript was accepted for publication on July 10, 2013. This manuscript was presented at the Spring Meeting of the Triological Society, Orlando, Florida, U.S.A., April 13, 2013. The authors have no funding, financial relationships, or conflicts of interest to disclose. DOI: 10.1002/lary.24332 Laryngoscope 124: February 2014 E34 the coding region of GJB2 has become routine, variability of auditory phenotype has become increasingly evident. Degree of hearing loss is known to range from profound deafness at birth to mild, progressive hearing loss presenting in late childhood, and is highly dependent on genotype.4 The ubiquity of GJB2-associated hearing loss around the world is notable for a highly prevalent genetic disease. Several mutant alleles have been described as being particularly prevalent: 35delG,5 found in Europe and the Middle East; 235delC,6 seen in East Asia; V37I,7 common in Southeast Asia; and W24X,2 predominant on the Indian subcontinent. Other mutations such as 167delT8 and R143W9 have been identified in very narrow populations—among the Ashkenazim and Ghanaians, respectively. We are interested in compiling and comparing the genotype frequencies for GJB2-associated hearing loss in different populations around the world. The purpose of this is twofold: 1) with the growing diversity of pediatric patient populations in urban centers around the world, it is crucial to understand the variability in GJB2associated hearing-loss phenotype and how it relates to country of origin; and 2) identifying patterns of GJB2 genotype between different populations may shed light on the evolutionary history and etiology of this form of Chan & Chang: Systematic Review of Cx-26-Associated Hearing Loss congenital hearing loss. Related to this second aim, we are also interested in examining the carrier frequencies of different mutant alleles associated with hearing loss. Finally, we wish to make use of the systematic review of articles pertaining to GJB2-associated hearing loss to perform meta-analyses of various aspects of the auditory phenotype in order to better understand the variability seen in this disorder. MATERIALS AND METHODS Systematic Review A search of Pubmed was undertaken on July 18, 2012, with the search parameter “(GJB2 OR Connexin 26 OR Cx26) AND (hearing OR deafness).” These parameters were chosen to yield a broad, comprehensive review of literature pertaining to GJB2-associated hearing loss. A total of 1,026 articles were thus identified. Titles and abstracts were screened, and 245 studies were chosen for full-length review according to the following criteria: a. Inclusion criteria i. Primary source ii. Report of allele and/or genotype frequencies for mutations in GJB2 in human subjects b. Exclusion criteria i. Specific statement in the abstract that complete DNA sequencing was not performed in all patients for identification of GJB2 mutations. The only exceptions to this criterion were made for articles that specifically state in the title or abstract that they report carrier rates of 35delG or V37I in the general population. ii. Patient population described specifically as having syndromic or autosomal dominant hearing loss, or hearing loss acquired as a result of known pre-, peri-, or postnatal ototoxic insult due to viral infection, jaundice, meningitis, or other condition. iii. Only one mutation analyzed or reported iv. Fewer than ten probands described v. Sample population reported in previous publication After full-length review, an additional 15 studies were excluded for not fulfilling these basic criteria, leaving 230 articles for further consideration for meta-analysis. The investigators (DKC and KWC) independently conducted this review and agreed upon the final included studies. GJB2 Genotype Frequency Using this library of 230 studies as a base, subsets of studies were selected for meta-analysis using the protocols listed below. An additional 14 studies were ultimately excluded for not fulfilling the inclusion and/or exclusion criteria for any of these meta-analyses, leaving 216 articles that were used in various subsets as follows (Fig. 1): 1. Prevalence of biallelic GJB2 hearing loss among all deaf probands a. Inclusion criteria i. Study population consisting of individuals with SNHL ii. Report of number of patients with biallelic GJB2associated hearing loss b. Exclusion criteria i. Original study cohort consisting exclusively of either DFNB1 or biallelic GJB2-hearing-loss probands ii. Complete DNA sequencing of all hearing-loss probands not performed Laryngoscope 124: February 2014 iii. Inability to ascertain the geographic origin for all subjects involved in the study. Specification of ethnic or racial background was not a requirement. c. From included studies, the number of hearing-impaired probands and confirmed biallelic GJB2-associated hearing-loss probands was extracted and combined across studies on the basis of country of origin. “Country of origin” is defined as the country in which the subject participated in the study, except in specific instances where a particular ethnic group was being studied, whose ancestral country of origin was reported. 2. Prevalence of the 35delG, 235delC, W24X, and V37I alleles among all individuals with biallelic GJB2-associated hearing loss. a. Inclusion criteria i. Study population consisting of individuals with SNHL ii. Specification of GJB2 genotype for all biallelic GJB2hearing-loss probands b. Exclusion criteria i. Complete DNA sequencing of all hearing-loss probands not performed ii. Inability to ascertain the geographic origin for all studies involved in the study. Specification of ethnic or racial background was not a requirement. c. From included studies, the number of 35delG, 235delC, W24X, and V37I alleles among all homozygotic and compound heterozygotic individuals with biallelic GJB2associated hearing loss was extracted for each allele separately and combined across studies on the basis of country of origin. For 35delG and V37I, due to their ubiquity, every included study was used for the analysis. For 235delC and W24X, the analysis was limited to countries in which either of these alleles was identified as the most common allele. 3. Carrier frequency of 35delG, 235delC, W24X, and V37I alleles among the general population a. Inclusion criterion i. Description of 35delG, 235delC, W24X, or V37I allele frequencies among the general population, without bias to hearing ability. Confirmation of normal hearing in this population was not required. b. Exclusion criterion i. Inability to ascertain the geographic origin for all studies involved in the study. Specification of ethnic or racial background was not a requirement. c. From included studies, the number of 35delG, 235delC, W24X, or V37I alleles among the general control population was extracted for each allele separately and combined across studies. 4. Case-control comparison of carrier frequency of 35delG, 235delC, W24X, and V37I alleles between hearing-impaired and general populations a. Inclusion criterion i. Rates of simple heterozygosity (carrier rates) reported for hearing-impaired and control general populations conducted in the same study. b. Exclusion criterion i. None c. From included studies, the number of 35delG, 235delC, W24X, or V37I alleles in simple heterozygosity among the hearing-impaired and general control population was extracted for each allele. Odds ratios and 95% confidence intervals were calculated for each study and pooled to obtain a summary effect using a random effects model (metan function, Stata 12.1, StataCorp, College Station, TX). Chan & Chang: Systematic Review of Cx-26-Associated Hearing Loss E35 Fig. 1. Included studies. The primary author (reference number), year of publication, and countries of origin of subjects is noted for each of the 216 included studies. For each study, the meta-analysis in which that study was included is indicated with an “X.” GJB2: meta-analysis of prevalence of biallelic GJB2-associated hearing loss among all hearing-loss probands. Allele frequency: meta-analysis of the prevalence of each specific allele among all biallelic GJB2-associated hearing-loss probands. Carrier frequency: meta-analysis of the prevalence of carriers of each specific allele among the general population. Case-control: meta-analysis of case-control studies comparing the prevalence of carriers of each specific allele among hearing-impaired cases and general population controls. Progression, symmetry, and inner-ear anomalies: meta-analysis of the prevalence of each of these phenotypic attributes among all biallelic GJB2-associated hearingloss probands. GJB2-Associated Hearing-Loss Phenotype Individual-level meta-analysis of progression, asymmetry, and inner-ear imaging anomalies in GJB2-associated hearingloss was performed. Studies were included from among the 230 studies identified in the systematic review if they provided prevalence data for any of these phenotypic findings among biallelic GJB2-associated hearing-loss probands. Appropriate data were extracted from studies reporting the prevalence of each of these properties and combined across studies. Strict definitions for progression, asymmetry, and inner-ear anomalies were not required, but were recorded when available. RESULTS Prevalence of Biallelic GJB2-Associated Hearing Loss Of the 230 articles identified from the systematic review, 175 articles met criteria for meta-analysis of Laryngoscope 124: February 2014 E36 GJB2 prevalence on a country-by-country basis (Fig. 1). An additional four studies were included for larger continent-wide analysis. These studies encompassed 43,530 hearing-loss probands and 7,518 individuals with biallelic GJB2-associated hearing loss, for a worldwide prevalence of 17.3%. The hearing-loss cohort varied from one study to another, with precise inclusion criteria occasionally available. Four broad categories were identified: 1) all hearing loss, unspecified; 2) congenital hearing loss; 3) nonsyndromic hearing loss; and 4) autosomal recessive nonsyndromic hearing loss. The respective rates of biallelic GJB2-associated hearing loss for these four groups were 12.3%, 16.9%, 18.1%, and 21.3%, consistent with the expected increase in prevalence as the patient cohort is narrowed down toward the nonsyndromic autosomal recessive inheritance pattern for GJB2. Each of these prevalence rates was statistically significantly different than one another (P < 0.0001, Chan & Chang: Systematic Review of Cx-26-Associated Hearing Loss Fig. 1. (Continued) Chi-squared test), except for the comparison between congenital and nonsyndromic hearing loss. Because of the imprecise definitions of patient cohorts in many studies, we elected to pool all studies regardless of initial patient cohort for the subsequent meta-analyses. Sixty-three countries were represented with at least one study distributed over all six inhabited continents (Figs. 2, 3). Prevalence was the highest in Europe (27.1%) and the lowest in sub-Saharan Africa (5.6%), but generally high throughout the world. The most common allele in each country is described in Figure 2 and Figure 4. 35delG is predominant throughout Europe, North Africa, and the Middle East, as well as areas populated largely by immigrants from these regions. The Indian subcontinent features W24X, whereas in East Asia 235delC and V37I are highly prevalent. Other specific populations were characterized by other mutations, including 167delC among the Ashkenazim in Israel and R143W in Ghana. Prevalence of 35delG- and V37I-Related Genotypes of Bi-Allelic GJB2-Associated Hearing Loss The allele and genotype frequencies of biallelic GJB2-associated hearing loss relating to the 35delG and Laryngoscope 124: February 2014 V37I alleles were assessed in every included study. These two alleles were chosen for this analysis because they represent opposite spectrums of the disease: 35delG is a truncating mutation predominant in much of the world and typically gives rise in homozygous form to profound congenital hearing loss,10 whereas V37I is a highly prevalent missense allele associated with a very mild hearing phenotype and high carrier rate in certain general populations.11 Of the 230 articles identified from the systematic review, 180 and 169 articles met criteria for metaanalysis of 35delG and V37I allele frequency, respectively, on a country-by-country basis. An additional six studies were included in larger continent-wide analysis for each allele. The allele frequencies for 35delG and V37I in each country are shown in Figures 2, 5, and 6. Worldwide, among all reported cases of bi-allelic GJB2-associated hearing loss, 35delG accounts for 57% of alleles, with allele frequencies in individual countries ranging from 0% in South and East Asian countries to 100% in Europe, North Africa, and the Middle East. The majority of these alleles (82.4%) are Chan & Chang: Systematic Review of Cx-26-Associated Hearing Loss E37 Fig. 1. (Continued) accounted for in 35delG homozygotes, with the remainder (17.6%) seen in compound heterozygosity with another disease-causing GJB2 allele. Overall, among all hearing-loss probands, the prevalence of 35delG homozygosity is 8.5%, and 35delG heterozygosity (including both simple and compound heterozygotes) is 5.3%. V37I, on the other hand, accounts for only 5.7% of all alleles reported worldwide. It is uncommon in most of Europe, but accounts for a large proportion of the alleles described in Taiwan, Thailand, Canada, Australia, and China. A total of 55.2% of alleles are accounted for by V37I/V37I homozygotes, and 44.8% are involved in compound heterozygosity. The prevalence values of V37I homozygotes and all heterozygotes among all hearing-loss probands are 6.9% and 19.6%, respectively. Prevalence of 235delC and W24X-Related Genotypes of Bi-Allelic GJB2-Associated Hearing Loss The 235delC and W24X alleles are important in East Asia and the Indian subcontinent, respectively. We analyzed the frequencies of these two alleles in each study where they represent the most common diseaseLaryngoscope 124: February 2014 E38 causing GJB2 allele (Fig. 2). For 235delC, 31 studies were thus identified, representing 9,781 hearing-loss probands, 1,625 (16.6%) of which had biallelic GJB2associated hearing loss. Twenty-five of these studies had sufficient genotype-specific data to allow meta-analysis. In seven countries (China, Japan, Korea, Taiwan, Thailand, Mongolia, and Russia), the overall allele frequency among biallelic GJB2-associated hearing-loss probands is 38.6%. W24X was identified as a major allele in 12 studies from seven countries (Bangladesh, India, Pakistan, Iran, Czech Republic, Turkey, and Spain). A total of 224 of 1424 (15.7%) hearing-loss probands had biallelic GJB2-associated hearing loss; among these individuals, the W24X allele accounted for 47.3% of all GJB2 mutations. Carrier Frequencies of GJB2 Alleles Associated With Hearing Loss The frequencies in the general population of GJB2 alleles associated with hearing loss was assessed (Fig. 2). Data from 52,715 normal-hearing controls from 115 studies across 55 countries reveals a worldwide carrier rate of 1.5% for 35delG. This ranged from 0% in multiple Chan & Chang: Systematic Review of Cx-26-Associated Hearing Loss Fig. 1. (Continued) countries to 5.7% in Belarus. V37I was even more disparate; worldwide, the carrier rate among 20,866 controls across 72 studies from 26 countries is 2.5%, ranging from 0% in most of these countries to as high as 16.7% in Thailand. Case-Control Study of Carrier Frequencies Comparison of carrier rates—specifically, the prevalence of simple heterozygotes of a particular allele— between hearing-impaired and control populations was performed. Thirty-five studies were identified that included carrier rates for 35delG in both hearingimpaired and control populations. The odds ratio (OR) for being a 35delG carrier given a history of hearing loss ranged widely, from 0.06912 to 22.3.13 Meta-analysis of these 35 studies using a random effects model yields a summary OR of 1.79 (95% CI: 1.29–2.48), indicating that 35delG carriers are relatively overrepresented among the hearing-loss cohort (Fig. 7). Two potential confounders for this finding are assortative mating and the presence of complementary genes. Assortative mating can be controlled for by only including studies where the hearing-loss cohort shows either Laryngoscope 124: February 2014 sporadic or autosomal recessive inheritance pattern, with no history of deafness beyond the proband and his/ her siblings. Limitation of the meta-analysis to 16 studies for which this inheritance pattern could be confirmed yielded a composite OR of 2.47 (95% CI: 1.55–3.95). This finding suggests that assortative mating does not play a role in the increased carrier rate among the hearingimpaired. The discovery of complementation of GJB2 mutations at the DFNB1 locus by the del(GJB6-D13S1830) deletion may also confound these results, as patients reported as simple heterozygotes without assessment of this locus would not be appropriately allocated. Limitation of the meta-analysis to 12 studies where the del(GJB6-D13S1830) was assessed yields a composite OR of 1.42 (95% CI: 0.76–2.65). Further narrowing to the five studies where both del(GJB6-D13S1830) was assessed, and hearing-loss probands have no family history of hearing loss gives a summary OR of 2.61 (95% CI: 0.69–9.80). These results suggest that there either remain additional complementary genes that have yet to have been discovered, or that being a carrier for 35delG indeed is associated with hearing loss, though with very limited penetrance. Chan & Chang: Systematic Review of Cx-26-Associated Hearing Loss E39 Fig. 1. (Continued) Meta-analysis of four case-control studies for the W24X allele yielded a similar summary OR of 2.06 (95% CI 0.33–13.07). When nine case-control studies for the 235delC allele were compared, a larger effect was seen; the summary OR was 4.55 (95% CI: 1.28– 16.13), even more strongly implicating the presence of complementary genes or a carrier phenotype. The majority of these studies did not address del(GJB6D13S1830), as it is very rare in South and East Asian populations. Overall, pooling all 48 case-control studies of the carrier rate of these three truncating mutations among hearing-impaired and normal control individuals yields an aggregate OR of 2.27 (95% CI: 1.53–3.36). There are, therefore, more than twice as many carriers among the hearing-impaired, as can be explained by the population allele frequency alone. The overall carrier rate in the general population across these 48 studies is 1.7%; taking into account the aggregate OR of 2.27, there would be an additional 2.2% of the hearing-impaired population whose carrier status is not explained by chance alone. This implies that either there are complementary genes that act together with GJB2 to account for 2.2% of Laryngoscope 124: February 2014 E40 all congenital hearing loss, or there is a carrier phenotype that is penetrant in a small fraction of carriers of truncating mutations in GJB2. Interestingly, when 18 case-control studies for carrier frequencies for the nontruncating mutation V37I were pooled, a summary OR of 0.78 (95% CI: 0.52–1.18) was observed (Fig. 8), which is significantly different from that observed for the aggregated truncating alleles. This suggests three possibilities: 1) hearing loss is not associated with the V37I carrier state; 2) there are no additional complementary genes that act in concert with V37I; or 3) a carrier effect or digenic inheritance occurs, but the phenotype is either very mild or minimally penetrant so as to be widely unrecognized. Different Disease-Causing Alleles of GJB2 Account for Similar Rates of Hearing Loss and Carriers in Disparate Populations GJB2-associated hearing loss is notable in that there are multiple independent alleles that are predominant in very disparate populations around the world, and that each of these alleles represents a major cause Chan & Chang: Systematic Review of Cx-26-Associated Hearing Loss Fig. 2. Distribution of common disease-causing variants in GJB2 around the world. For each country, composite values obtained from meta-analyses of systematically reviewed studies are presented. Most common allele: the most highly prevalent disease-causing GJB2 variant among all biallelic GJB2 probands. Biallelic GJB2 prevalence: prevalence of biallelic GJB2-associated hearing loss among all hearing-loss probands. Allele frequency: frequency of each specified allele among all biallelic GJB2-associated hearingloss probands. Data for 35delG and V37I are presented for all countries with available data; for countries where neither 35delG nor V37I are the most common allele, the allele frequency is presented for the most common allele. Carrier frequency: frequency of simple carriers of each specified allele among the general population. Data for 35delG and V37I are presented for all countries with available data; for countries where neither 35delG nor V37I are the most common allele, the allele frequency is presented for the most common allele. of congenital hearing loss in each of these populations. To quantify and compare this, we grouped countries according to the most common allele present in that country and calculated for each group: 1) the prevalence among all hearing-loss probands of biallelic GJB2 associated hearing-loss; 2) frequency among these individuals of the most common allele in that population; and 3) carrier frequency among the general population. Results are shown in Figure 9. 35delG was by far the most widely distributed allele, accounting for the majority of alleles in 47 countries. However, multiple countries, accounting for large geographic areas and proportions of the world’s population, feature other alleles, specifically 235delC, W24X, and V37I. Finally, three other distinct mutations were identified as highly prevalent in Israel, Ghana, and Mongolia. Focusing on Laryngoscope 124: February 2014 the three most important truncating mutations— 35delG, 235delC, and W24X—the prevalence of biallelic GJB2-associated hearing loss (range: 11%–18%), frequency of the allele (50%–52%), and carrier frequency (0.7%–1.7%) is remarkably similar across all three large populations. The countries in which these three mutations are endemic together account for 68.4% of the world’s population; in contrast, countries in which the rate of GJB2-associated hearing has been reported to be low or nonexistent only make up 5.1% of the world’s population. The widespread existence of these mutations as the major cause of congenital hearing loss in these disparate populations attests to the importance of this gene in hearing function, and also suggests the likelihood of a wider evolutionary significance to alterations in GJB2. Chan & Chang: Systematic Review of Cx-26-Associated Hearing Loss E41 Fig. 2. (Continued) GJB2-Associated Hearing-Loss Phenotype Variability in severity of hearing loss, and its dependence on genotype, has been well documented previously.4 Progression of hearing loss has varied widely between studies. Meta-analysis of 28 studies presenting progression data on 1,140 patients yielded an overall progression rate of 18.7% (range: 0%–56.0%). All but seven articles provided a precise definition for progression; an additional four used only patient report of postlingual onset as a definition for progression. The remaining 17 all had strict audiologic criteria for progression. The rate of asymmetry was similarly calculated over 19 studies encompassing 801 biallelic GJB2-associated hearing-loss probands to be 14.2% (range: 0%–55.6%). A total of 13/19 studies had objective criteria presented to define asymmetric hearing loss. Finally, the incidence of imaging abnormalities among this population was assessed in 10 studies. A total of 16% (range: 3.1%–76.9%) of the 406 patients tested had some imaging abnormality. DISCUSSION Over the past 15 years, tremendous amounts of epidemiologic data have been collected regarding GJB2Laryngoscope 124: February 2014 E42 associated hearing loss around the world. This study is an attempt to synthesize these data to serve as both a reference for clinicians working up and counseling patients with congenital SNHL, and to provide strong evidence on a large scale that corroborates findings of 1) increased carrier rates among the hearing impaired (which suggests the existence of additional complementary genes or a true carrier phenotype) and 2) widespread prevalence of distinct GJB2 mutations around the world (which suggests an evolutionary advantage conferred by mutations in GJB2). Limitations of the Study The primary limitation of this study is the heterogeneity of the included studies. Specifically, the starting population of hearing-loss probands was quite varied between studies, and was not precisely defined for the majority. This heterogeneity made it impossible to precisely define meaningful subgroups of hearing-loss probands; therefore, we elected to group all studies for our analysis. The vast majority of studies specifically excluded syndromic forms of hearing loss. Although we included some studies that did not address inclusion of syndromic hearing loss, we Chan & Chang: Systematic Review of Cx-26-Associated Hearing Loss Fig. 3. Prevalence of GJB2-associated hearing loss among all hearing-loss probands. Percentage of individuals with hearing loss having two disease-causing mutations in GJB2 in shown. Countries with no data are shown in gray. [Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.] did exclude studies that exclusively looked at syndromic subjects. Specification of suspected genetic attribution and the presumed inheritance pattern was very heterogeneous. Commonly excluded acquired forms of congenital hearing loss were congenital viral infections associated with hearing loss, neonatal jaundice, and meningitis. A fraction of the studies limited their cohort to individuals with an inheritance pattern consistent with autosomal Fig. 4. The most common GJB2 mutation. The most common GJB2 mutation found in each country is shown. Countries where no instances of biallelic GJB2-associated hearing loss are shown in black. Countries with no data are shown in gray. [Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.] Laryngoscope 124: February 2014 Chan & Chang: Systematic Review of Cx-26-Associated Hearing Loss E43 Fig. 5. The 35delG allele frequency. The prevalence of the 35delG allele among all cases of biallelic GJB2-associated hearing loss is shown. [Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.] recessive inheritance (either multiple affected siblings with unaffected parents, or sporadic cases). Other common, specific exclusion criteria among the studies were the presence of hearing loss that was unilateral, postlingual, or mild-moderate in severity (including a number of studies specifically on patients undergoing cochlear implantation). A handful of studies were limited to children, but the majority did not specify age. Certain specific findings of allele frequencies in different countries are likely highly dependent on the particular population samples, and are thus subject to sampling bias. For example, the high rate of V37I in Canada is likely attributable to one study14 with a disproportionately high percentage of East Asian probands, which is not reflective of the Canadian population as a whole. Most studies do not specify the ethnic or racial Fig. 6. The V37I allele frequency. The prevalence of the V37I allele among all cases of biallelic GJB2-associated hearing loss is shown. [Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.] Laryngoscope 124: February 2014 E44 Chan & Chang: Systematic Review of Cx-26-Associated Hearing Loss Fig. 7. Carrier-rate meta-analysis for truncating mutations. Odds ratios (ORs) and 95% confidence intervals were calculated for carrier rates of three truncating mutations—35delG, 235delC, and W24X—in case-control studies examining the carrier rate in hearing-impaired cases and unaffected general population controls. ORs to the right of the vertical black line indicate higher odds of being a carrier of one of these mutations in the hearing-impaired population. Meta-analyses using a random-effects model yielded summary ORs and confidence intervals. *Studies where exclusively sporadic cases of hearing loss were evaluated. # studies in which del(GJB6-D13S1830) was evaluated. background of their study population, and this analysis is limited to geography, not ethnicity. This is particularly important to note in countries in North America, South America, and Australia, where urban, academic centers feature high proportions of immigrant populations from around the world. Conversely, small studies in countries Laryngoscope 124: February 2014 with highly compartmentalized ethnic populations, such as many African and Asian countries, may misrepresent the GJB2 prevalence in those ethnic groups not represented in the study performed. China, which is itself a very large and heterogeneous country, was not subjected to finer analysis based on subregion; in many instances, Chan & Chang: Systematic Review of Cx-26-Associated Hearing Loss E45 Fig. 8. Carrier-rate meta-analysis for V37I. Odds ratios (ORs) and 95% confidence intervals were calculated for carrier rates of V37I, a non-truncating mutation, in case-control studies examining the carrier rate in hearing-impaired cases and unaffected general population controls. ORs to the right of the vertical black line indicate higher odds of being a carrier of V37I in the hearing-impaired population. Meta-analysis using a random-effects model yielded a summary OR and 95% confidence interval. the subject group consisted of individuals from deaf schools, for whom subregion of origin was not specified. Both 235delC and V37I were highly prevalent in a number of studies, with a trend toward 235delC being more common in northern China and V37I prevalent in southern China, consistent with the patterns in neighboring countries. In general, prevalence data for V37I-related genotypes may be underreported, especially in older studies, depending on whether the V37I allele was considered disease-causing. It is not clear in all studies whether V37I was not reported due to this uncertainty. Because of the uncertainty about V37I reporting and subregion of origin, we elected to analyze China as a whole. Despite these uncertainties with regards to ethnicity, where general patterns are consistent and patient numbers are high, robust conclusions can be made; this is certainly true for 35delG in Europe, North Africa, and the Middle East, 235delC in East Asia, V37I in Southeast Asia, and W24X in the Indian subcontinent. Finally, other than one study in which progression was associated with the V37I exclusive genotype,11 phenotypic findings of progression, asymmetry, and concomitant imaging abnormalities were not reported together with specific genotypes. Rather, these attributes were calculated for all pooled biallelic GJB2 hearing-loss proLaryngoscope 124: February 2014 E46 bands. Thus, they are subject to the particular genotypic mix represented in the included studies. This is particularly significant for progression of hearing loss; although some studies specifically limited the analysis of progression to patients who initially presented with less than severe hearing loss, the majority did not. Inclusion of patients in a progression analysis based only on the presence of multiple audiograms without exclusion of those with initial severe or profound hearing loss may lead to underreporting of the rate of progression among patients for whom progression is more relevant—those with only mild or moderate hearing loss. Because the majority of studies where progression was calculated featured 35delG/35delG as the most common genotype, and this genotype is typically associated with bilateral severe-to-profound hearing loss at presentation, the reported aggregate rate of 18.7% progression is likely an underestimate for genotypes that present with more mild hearing loss. Furthermore, owing to the particular inclusion criteria of this systematic review, which was not expressly designed to capture all studies addressing phenotype of GJB2-associated hearing loss, the metaanalyses of progression, symmetry, and imaging abnormalities, while relatively large in sample size, might not include all relevant studies. Chan & Chang: Systematic Review of Cx-26-Associated Hearing Loss Fig. 9. Genotype and allele prevalence rates across mutations. For each of six mutations—35delG, 235delC, W24X, V37I, R143W, and 167delT—data were pooled for each mutation across the countries in which they represented the most common mutation. (A) Prevalence of biallelic GJB2-associated hearing loss among all hearing-loss probands; (B) carrier frequency among unaffected general population controls; and (C) allele frequency among all biallelic GJB2-associated hearing-loss probands are shown for each of these six mutations. (D) Percentage of the world’s population accounted for by countries in which each of these six alleles are found in significant abundance among both the hearing-impaired and the general population. Countries in which GJB2 alleles have been evaluated, and which have very low or non-existent rates of GJB2 mutations are shown in black. Countries in which GJB2 allele frequencies have not been assessed are indicated in gray. [Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.] Genotype and Ethnicity: An Evolutionary Advantage Associated With Mutations in GJB2? Biallelic GJB2-hearing loss is common throughout the world; it accounts for greater than 10% of all SNHL probands in all major regions of the world except for sub-Saharan Africa. Specific alleles correlate highly with geography. In Europe, the Middle East, and North Africa, and by extension owing to immigration patterns, North and South America, and Australia, 35delG is predominant. In East Asia 235delC and V37I are very common, and W24X dominates the Indian subcontinent. Laryngoscope 124: February 2014 Together with R143W, which is highly prevalent in Ghana, and 167delT, which is found in high frequency among the Ashkenazim, these represent a total of six independently arisen mutations that have come to represent the most prevalent single cause of congenital SNHL in six disparate populations around the world, which in aggregate account for almost 70% of the world’s population. The high carrier frequencies of each of these mutations among the general population in which they are endemic, which range from 0.7% to 16%, comparable to those of some of the most common genetic disorders, Chan & Chang: Systematic Review of Cx-26-Associated Hearing Loss E47 including cystic fibrosis and sickle-cell anemia, further support the supposition that these mutations are unusually prevalent in so many distinct populations. This finding suggests that there may be an evolutionary advantage to being a carrier for a mutation in GJB2, which has led to the widespread persistence of these multiple mutations after each independently arose in each of these different populations. Dominant-negative mutations in GJB2 are associated with hyperkeratosis in the context of KID syndrome. The expression of Cx26 in the epidermis raises the possibility of a skin-based protective advantage, perhaps related to susceptibility to skin barrier breakdown, infection, or neoplasm. Epidermal thickening has been described in both 35delG15and R143W16 heterozygotes, R143W-transfected epithelial cells display resistance to cell death,17 and Cx26 signaling has been implicated in Shigella-based bacterial invasion.18 The precise mechanism for this protection merits further investigation. Carrier Rate Is Significantly Higher Among Hearing-Impaired Individuals Meta-analysis of case-control studies of carrier rates of pathogenic mutations in GJB2 between hearingimpaired and normal control populations revealed a significantly higher carrier rate among the hearing-impaired for 35delG, W24X, and 235delC, but not for V37I. Three possible causes of this disparity could be assortative mating, unidentified complementary mutations, and the presence of a variably penetrant carrier phenotype. Subgroup analysis suggested that assortative mating does not contribute to this phenomenon. The complementary mutation hypothesis suggests that there are either unidentified mutations in regulatory elements that act together with the known mutation to effectively lead to a biallelic mutation, as has been demonstrated for del(GJB6-D13S1830) and del(GJB6-D13S1834),19,20 or completely separate genes that act together with GJB2 in a digenic manner to lead to hearing loss. Such modifiers and regulatory elements have not yet been identified.21,22 The fact that the disparity in carrier frequencies is not significantly different between 35delG, W24X, and 235delC suggests that such unidentified mutations would be widespread, or else multiply independently arisen in these three populations, which seems unlikely. Furthermore, the finding that there is a significant difference between the truncating mutations (35delG, 235delC, and W24X) and the nontruncating mutation (V37I) in terms of the disparity in carrier frequency makes either a widespread GJB2 regulatory-element mutation or digenic hypothesis somewhat less attractive, though one could imagine a complementary mutation present worldwide that exhibits a digenic inheritance pattern with severe mutations, but not with a mild mutation. Assuming, however, that such a complementary mutation would lead to hearing loss in conjunction with either a truncating or a nontruncating mutation, the existence of a widespread mutation complementing 35delG, W24X, and 235delC, but not V37I would not fit with the ethnic distribution of these four alleles: there is Laryngoscope 124: February 2014 E48 significant population overlap between 235delC and V37I, which are both found in East Asia, and not between 235delC, 35delG, and W24X. More likely is that the three truncating mutations have a variably penetrant carrier phenotype. That is, in some individuals, missing one functional copy of the GJB2 gene leads to hearing loss. This may be due to epigenetic allelic inactivation of the normal copy in some individuals, or perhaps due to a gene dosage effect. Gap junctions in the cochlea are formed as heterotypic heteromers between Cx26 and Cx30; altering the gene dosage of Cx26 could alter the stoichiometry of these gap junctions and affect their function. In contrast to the truncating mutations, where either gene dosage or inactivation effects could lead to significant effects on gapjunction integrity, the nontruncating mutation V37I, which even in homozygosity leads only to mild hearing loss, would not be expected to have a significant effect on cochlear function and hearing. Overall, however, it is not possible to definitively distinguish between the digenic inheritance and carrier phenotype hypotheses in this study. Further in-depth pedigree analysis and focused genomic investigation is required to evaluate this further. Auditory Phenotype Is Highly Variable Snoeckx et al.4 demonstrated in a very large cohort that severity of hearing loss was highly variable and dependent on genotype. The meta-analyses performed here on progression, asymmetry, and concomitant imaging abnormalities corroborate the high degree of variability of the audiologic phenotype, and highlight the importance of complete sequencing of the coding region of GJB2 in all cases of congenital or early-onset SNHL. Patients with clearly syndromic or autosomal dominant hearing loss, as well as those with clearly identified causes of hearing loss, such as congenital CMV infection, meningitis, were usually excluded from these studies, and this meta-analysis cannot address whether GJB2 sequencing is indicated in these cases. Subjects with unilateral hearing loss were also excluded at times; the finding that 14.2% of subjects reported had some asymmetry, though, suggests that even those with unilateral hearing loss may be at risk for harboring pathogenic mutations in GJB2, and should be considered for genetic analysis.23 The variability in auditory phenotype may reflect the role of Connexin 26 in cochlear function, and the pathophysiology of how dysfunction of Connexin 26 leads to hearing loss. The contribution of Connexin 26-based epithelial and connective-tissue gap junction networks in the cochlea to sensory transduction is not completely described. Important roles in potassium recycling, intercellular calcium signaling, and electrical coupling to support electromotile cochlear amplification have been proposed.24,25 In most animal models of Connexin 26associated hearing loss, loss of hair cells, which do not express Connexin 26, is a relatively delayed finding.26–28 There is likely, then, a cascade of pathophysiological events that must take place for gap-junction dysfunction Chan & Chang: Systematic Review of Cx-26-Associated Hearing Loss to lead to hair-cell dysfunction and hearing loss; genetic and environmental variability in how these mechanisms propagate would underlie the phenotypic variability. More investigation into genetic modifiers that underlie this variability, as well as the pathophysiological mechanisms that are modified, is crucial to understand the pathway involved and develop treatments that can be aimed at preventing progression of hearing loss and even hearing restoration. CONCLUSION This systematic review and meta-analysis confirms that biallelic GJB2-associated hearing loss is nearly universally highly prevalent around the world. Phenotype is highly variable, and correlates with genotype; genotype, in turn, is highly dependent on geography. Multiply-arisen, highly-prevalent mutations suggest the possibility of an evolutionary advantage to being a carrier for a GJB2 mutation. Conversely, analysis of carrier rates suggests that even carriers of GJB2 mutations are at higher risk for hearing loss, even without invoking the presence of additional complementary mutations. Overall, the wide genetic and phenotypic variability associated with this most common form of congenital SNHL invites significant investigation into its genomic and pathophysiologic mechanisms. BIBLIOGRAPHY 1. Morton CC, Nance WE. Newborn hearing screening—a silent revolution. N Engl J Med 2006;354:2151–2164. 2. Kelsell DP, Dunlop J, Stevens HP, et al. Connexin 26 mutations in hereditary non-syndromic sensorineural deafness. Nature 1997;387:80–83. 3. Ballana E, Ventayol M, Rabionet R, Gasparini P, Estivill X. Connexins and deafness homepage. http://www.crg.es/deafness. Accessed March 13, 2013. 4. Snoeckx RL, Huygen PL, Feldmann D, et al. GJB2 mutations and degree of hearing loss: a multicenter study. Am J Hum Genet 2005;77:945–957. 5. Denoyelle F, Weil D, Maw MA, et al. Prelingual deafness: high prevalence of a 30delG mutation in the connexin 26 gene. Hum Mol Genet 1997;6: 2173–2177. 6. Fuse Y, Doi K, Hasegawa T, Sugii A, Hibino H, Kubo T. Three novel connexin26 gene mutations in autosomal recessive non-syndromic deafness. Neuroreport 1999;10:1853–1857. 7. Kelley PM, Harris DJ, Comer BC et al. Novel mutations in the connexin 26 gene (GJB2) that cause autosomal recessive (DFNB1) hearing loss. Am J Hum Genet 1998;62:792–799. 8. Zelante L, Gasparini P, Estivill X et al. Connexin26 mutations associated with the most common form of non-syndromic neurosensory autosomal recessive deafness (DFNB1) in Mediterraneans. Hum Mol Genet 1997;6: 1605–1609. 9. Brobby GW, Muller-Myhsok B, Horstmann RD. Connexin 26 R143W mutation associated with recessive nonsyndromic sensorineural deafness in Africa. N Engl J Med 1998;338:548–550. 10. Denoyelle F, Marlin S, Weil D, et al. Clinical features of the prevalent form of childhood deafness, DFNB1, due to a connexin-26 gene defect: implications for genetic counselling. Lancet 1999;353:1298–1303. 11. Chan DK, Schrijver I, Chang KW. Connexin-26-associated deafness: phenotypic variability and progression of hearing loss. Genet Med 2010;12: 174–181. 12. Al-Qahtani MH, Baghlab I, Chaudhary AG, et al. Spectrum of GJB2 mutations in a cohort of nonsyndromic hearing loss cases from the Kingdom of Saudi Arabia. Genet Test Mol Biomarkers 2010;14:79–83. 13. Gazzaz B, Weil D, Rais L, Akhyat O, Azeddoug H, Nadifi S. Autosomal recessive and sporadic deafness in Morocco: high frequency of the 35delG GJB2 mutation and absence of the 342-kb GJB6 variant. Hear Res 2005;210:80–84. 14. Huculak C, Bruyere H, Nelson TN, Kozak FK, Langlois S. V37I connexin 26 allele in patients with sensorineural hearing loss: evidence of its pathogenicity. Am J Med Genet A 2006;140:2394–2400. 15. D’Adamo P, Guerci VI, Fabretto A et al. Does epidermal thickening explain GJB2 high carrier frequency and heterozygote advantage? Eur J Hum Genet 2009;17:284–286. 16. Meyer CG, Amedofu GK, Brandner JM, Pohland D, Timmann C, Horstmann RD. Selection for deafness? Nat Med 2002;8:1332–1333. Laryngoscope 124: February 2014 17. Common JE, Di WL, Davies D, Kelsell DP. Further evidence for heterozygote advantage of GJB2 deafness mutations: a link with cell survival. J Med Genet 2004;41:573–575. 18. Tran Van Nhieu G, Clair C, Bruzzone R, Mesnil M, Sansonetti P, Combettes L. Connexin-dependent inter-cellular communication increases invasion and dissemination of Shigella in epithelial cells. Nat Cell Biol 2003;5:720–726. 19. Rodriguez-Paris J, Schrijver I. The digenic hypothesis unraveled: the GJB6 del(GJB6-D13S1830) mutation causes allele-specific loss of GJB2 expression in cis. Biochem Biophys Res Commun 2009;389:354–359. 20. Rodriguez-Paris J, Tamayo ML, Gelvez N, Schrijver I. Allele-specific impairment of GJB2 expression by GJB6 deletion del(GJB6-D13S1854). PLoS One 2011;6:e21665. 21. Hilgert N, Huentelman MJ, Thorburn AQ, et al. Phenotypic variability of patients homozygous for the GJB2 mutation 35delG cannot be explained by the influence of one major modifier gene. Eur J Hum Genet 2009;17: 517–524. 22. Pollak A, Mueller-Malesinska M, Skorka A, et al. GJB2 and hearing impairment: promoter defects do not explain the excess of monoallelic mutations. J Med Genet 2008;45:607–608. 23. Chan DK, Schrijver I, Chang KW. Diagnostic yield in the workup of congenital sensorineural hearing loss is dependent on patient ethnicity. Otol Neurotol 2011;32:81–87. 24. Mammano F. Ca21 homeostasis defects and hereditary hearing loss. Biofactors 2011;37:182–188. 25. Hoang Dinh E, Ahmad S, Chang Q, Tang W, Stong B, Lin X. Diverse deafness mechanisms of connexin mutations revealed by studies using in vitro approaches and mouse models. Brain Res 2009;1277:52–69. 26. Cohen-Salmon M, Ott T, Michel V et al. Targeted ablation of connexin26 in the inner ear epithelial gap junction network causes hearing impairment and cell death. Curr Biol 2002;12:1106–1111. 27. Kudo T, Kure S, Ikeda K, et al. Transgenic expression of a dominantnegative connexin26 causes degeneration of the organ of Corti and nonsyndromic deafness. Hum Mol Genet 2003;12:995–1004. 28. Wang Y, Chang Q, Tang W, et al. Targeted connexin26 ablation arrests postnatal development of the organ of Corti. Biochem Biophys Res Commun 2009;385:33–37. 29. Estivill X, Fortina P, Surrey S, et al. Connexin-26 mutations in sporadic and inherited sensorineural deafness. Lancet 1998;351:394–398. 30. Lench N, Houseman M, Newton V, Camp GV, Mueller R. Connexin-26 mutations in sporadic non-syndromal sensorineural deafness. Lancet 1998;351:415. 31. Morell RJ, Kim HJ, Hood LJ, et al. Mutations in the connexin 26 gene (GJB2) among Ashkenazi Jews with nonsyndromic recessive deafness. N Engl J Med 1998;339:1500–1505. 32. Antoniadi T, Rabionet R, Kroupis C, et al. High prevalence in the Greek population of the 35delG mutation in the connexin 26 gene causing prelingual deafness. Clin Genet 1999;55:381–382. 33. Cohn ES, Kelley PM, Fowler TW, et al. Clinical studies of families with hearing loss attributable to mutations in the connexin 26 gene (GJB2/ DFNB1). Pediatrics 1999;103:546–550. 34. Green GE, Scott DA, McDonald JM, Woodworth GG, Sheffield VC, Smith RJ. Carrier rates in the midwestern United States for GJB2 mutations causing inherited deafness. JAMA 1999;281:2211–2216. 35. Mueller RF, Nehammer A, Middleton A, et al. Congenital non-syndromal sensorineural hearing impairment due to connexin 26 gene mutations— molecular and audiological findings. Int J Pediatr Otorhinolaryngol 1999;50:3–13. 36. Murgia A, Orzan E, Polli R et al. Cx26 deafness: mutation analysis and clinical variability. J Med Genet 1999;36:829–832. 37. Storm K, Willocx S, Flothmann K, Van Camp G. Determination of the carrier frequency of the common GJB2 (connexin-26) 35delG mutation in the Belgian population using an easy and reliable screening method. Hum Mutat 1999;14:263–266. 38. Abe S, Usami S, Shinkawa H, Kelley PM, Kimberling WJ. Prevalent connexin 26 gene (GJB2) mutations in Japanese. J Med Genet 2000;37:41– 43. 39. Gasparini P, Rabionet R, Barbujani G, et al. High carrier frequency of the 35delG deafness mutation in European populations. Genetic Analysis Consortium of GJB2 35delG. Eur J Hum Genet 2000;8:19–23. 40. Kudo T, Ikeda K, Kure S et al. Novel mutations in the connexin 26 gene (GJB2) responsible for childhood deafness in the Japanese population. American J Med Genet 2000;90:141–145. 41. Lerer I, Sagi M, Malamud E, Levi H, Raas-Rothschild A, Abeliovich D. Contribution of connexin 26 mutations to nonsyndromic deafness in Ashkenazi patients and the variable phenotypic effect of the mutation 167delT. American J Med Genet 2000;95:53–56. 42. Masmoudi S, Elgaied-Boulila A, Kassab I, et al. Determination of the frequency of connexin26 mutations in inherited sensorineural deafness and carrier rates in the Tunisian population using DGGE. J Med Genet 2000;37:E39. 43. Milunsky JM, Maher TA, Yosunkaya E, Vohr BR. Connexin-26 gene analysis in hearing-impaired newborns. Genet Test 2000;4:345–349. 44. Park HJ, Hahn SH, Chun YM, Park K, Kim HN. Connexin26 mutations associated with nonsyndromic hearing loss. Laryngoscope 2000;110: 1535–1538. 45. Prasad S, Cucci RA, Green GE, Smith RJ. Genet Test for hereditary hearing loss: connexin 26 (GJB2) allele variants and two novel deafness- Chan & Chang: Systematic Review of Cx-26-Associated Hearing Loss E49 46. 47. 48. 49. 50. 51. 52. 53. 54. 55. 56. 57. 58. 59. 60. 61. 62. 63. 64. 65. 66. 67. 68. 69. 70. 71. 72. 73. causing mutations (R32C and 645–648delTAGA). Hum Mutat 2000;16: 502–508. Rabionet R, Zelante L, Lopez-Bigas N, et al. Molecular basis of childhood deafness resulting from mutations in the GJB2 (connexin 26) gene. Hum Genet 2000;106:40–44. Sobe T, Vreugde S, Shahin H, et al. The prevalence and expression of inherited connexin 26 mutations associated with nonsyndromic hearing loss in the Israeli population. Hum Genet 2000;106:50–57. Wilcox SA, Saunders K, Osborn AH, et al. High frequency hearing loss correlated with mutations in the GJB2 gene. Hum Genet 2000;106:399– 405. Gabriel H, Kupsch P, Sudendey J, Winterhager E, Jahnke K, Lautermann J. Mutations in the connexin26/GJB2 gene are the most common event in non-syndromic hearing loss among the German population. Hum Mutat 2001;17:521–522. Hamelmann C, Amedofu GK, Albrecht K, et al. Pattern of connexin 26 (GJB2) mutations causing sensorineural hearing impairment in Ghana. Hum Mutat 2001;18:84–85. Kenna MA, Wu BL, Cotanche DA, Korf BR, Rehm HL. Connexin 26 studies in patients with sensorineural hearing loss. Arch Otolaryngol Head Neck Surg 2001;127:1037–1042. Kudo T, Ikeda K, Oshima T, et al. GJB2 (connexin 26) mutations and childhood deafness in Thailand. Otol Neurotol 2001;22:858–861. Loffler J, Nekahm D, Hirst-Stadlmann A, et al. Sensorineural hearing loss and the incidence of Cx26 mutations in Austria. Eur J Hum Genet 2001; 9:226–230. Lucotte G, Bathelier C, Champenois T. PCR test for diagnosis of the common GJB2 (connexin 26) 35delG mutation on dried blood spots and determination of the carrier frequency in France. Mol Cell Probes 2001; 15:57–59. Mustapha M, Salem N, Delague V, et al. Autosomal recessive nonsyndromic hearing loss in the Lebanese population: prevalence of the 30delG mutation and report of two novel mutations in the connexin 26 (GJB2) gene. J Med Genet 2001;38:E36. Simsek M, Al-Wardy N, Al-Khayat A, et al. Absence of deafness-associated connexin-26 (GJB2) gene mutations in the Omani population. Hum Mutat 2001;18:545–546. Tekin M, Akar N, Cin S, et al. Connexin 26 (GJB2) mutations in the Turkish population: implications for the origin and high frequency of the 35delG mutation in Caucasians. Hum Genet 2001;108:385–389. Toth T, Kupka S, Esmer H, et al. Frequency of the recessive 30delG mutation in the GJB2 gene in Northeast-Hungarian individuals and patients with hearing impairment. Int J Mol Med 2001;8:189–192. Wiszniewski W, Sobieszczanska-Radoszewska L, Nowakowska-Szyrwinska E, Obersztyn E, Bal J. High frequency of GJB2 gene mutations in Polish patients with prelingual nonsyndromic deafness. Genet Test 2001;5:147– 148. Frei K, Szuhai K, Lucas T, et al. Connexin 26 mutations in cases of sensorineural deafness in eastern Austria. Eur J Hum Genet 2002;10:427– 432. Gualandi F, Ravani A, Berto A, et al. Exploring the clinical and epidemiological complexity of GJB2-linked deafness. Am J Med Genet 2002;112: 38–45. Iliades T, Eleftheriades N, Iliadou V, et al. Prelingual Nonsyndromic Hearing Loss in Greece. ORL J Otorhinolaryngol Relat Spec 2002;64:321– 323. Janecke AR, Hirst-Stadlmann A, Gunther B, et al. Progressive hearing loss, and recurrent sudden sensorineural hearing loss associated with GJB2 mutations—phenotypic spectrum and frequencies of GJB2 mutations in Austria. Hum Genet 2002;111:145–153. Kupka S, Braun S, Aberle S, et al. Frequencies of GJB2 mutations in German control individuals and patients showing sporadic non-syndromic hearing impairment. Hum Mutat 2002;20:77–78. Liu XZ, Xia XJ, Ke XM, et al. The prevalence of connexin 26 (GJB2) mutations in the Chinese population. Hum Genet 2002;111:394–397. Liu Y, Ke X, Qi Y, Li W, Zhu P. Connexin26 gene (GJB2): prevalence of mutations in the Chinese population. J Hum Genet 2002;47:688–690. Medlej-Hashim M, Mustapha M, Chouery E, et al. Non-syndromic recessive deafness in Jordan: mapping of a new locus to chromosome 9q34.3 and prevalence of DFNB1 mutations. Eur J Hum Genet 2002;10:391– 394. Najmabadi H, Cucci RA, Sahebjam S, et al. GJB2 mutations in Iranians with autosomal recessive non-syndromic sensorineural hearing loss. Hum Mutat 2002;19:572. Oliveira CA, Maciel-Guerra AT, Sartorato EL. Deafness resulting from mutations in the GJB2 (connexin 26) gene in Brazilian patients. Clin Genet 2002;61:354–358. Orzan E, Murgia A, Polli R, et al. Connexin 26 preverbal hearing impairment: mutation prevalence and heterozygosity in a selected population. Int J Audiol 2002;41:120–124. Pampanos A, Economides J, Iliadou V, et al. Prevalence of GJB2 mutations in prelingual deafness in the Greek population. Int J Pediatr Otorhinolaryngol 2002;65:101–108. Shahin H, Walsh T, Sobe T, et al. Genetics of congenital deafness in the Palestinian population: multiple connexin 26 alleles with shared origins in the Middle East. Hum Genet 2002;110:284–289. Wang YC, Kung CY, Su MC, et al. Mutations of Cx26 gene (GJB2) for prelingual deafness in Taiwan. Eur J Hum Genet 2002;10:495–498. Laryngoscope 124: February 2014 E50 74. Wu BL, Lindeman N, Lip V, et al. Effectiveness of sequencing connexin 26 (GJB2) in cases of familial or sporadic childhood deafness referred for molecular diagnostic testing. Genet Med 2002;4:279–288. 75. Zoll B, Petersen L, Lange K, et al. Evaluation of Cx26/GJB2 in German hearing impaired persons: mutation spectrum and detection of disequilibrium between M34T (c.101T>C) and 2493del10. Hum Mutat 2003;21: 98. 76. Bayazıt YA, Cable BB, Cataloluk O, et al. GJB2 gene mutations causing familial hereditary deafness in Turkey. Int J Pediatr Otorhinolaryngol 2003;67:1331–1335. 77. Gurtler N, Kim Y, Mhatre A, Muller R, Probst R, Lalwani AK. GJB2 mutations in the Swiss hearing impaired. Ear Hear 2003;24:440–447. 78. Hwa HL, Ko TM, Hsu CJ, et al. Mutation spectrum of the connexin 26 (GJB2) gene in Taiwanese patients with prelingual deafness. Genet Med 2003;5:161–165. 79. Lim LH, Bradshaw JK, Guo Y, et al. Genotypic and phenotypic correlations of DFNB1-related hearing impairment in the Midwestern United States. Arch Otolaryngol Head Neck Surg 2003;129:836–840. 80. Lopponen T, Vaisanen ML, Luotonen M, et al. Connexin 26 mutations and nonsyndromic hearing impairment in northern Finland. Laryngoscope 2003;113:1758–1763. 81. Lucotte G, Pinna A. Elevated frequencies of the 35delG allele of the connexin 26 gene in Corsica, France. Clin Genet 2003;64:517–518. 82. Maheshwari M, Vijaya R, Ghosh M, Shastri S, Kabra M, Menon PS. Screening of families with autosomal recessive non-syndromic hearing impairment (ARNSHI) for mutations in GJB2 gene: Indian scenario. Am J Med Genet A 2003;120A:180–184. 83. Ohtsuka A, Yuge I, Kimura S, et al. GJB2 deafness gene shows a specific spectrum of mutations in Japan, including a frequent founder mutation. Hum Genet 2003;112:329–333. 84. Pandya A, Arnos KS, Xia XJ, et al. Frequency and distribution of GJB2 (connexin 26) and GJB6 (connexin 30) mutations in a large North American repository of deaf probands. Genet Med 2003;5:295–303. 85. Tekin M, Duman T, Bogoclu G, et al. Spectrum of GJB2 mutations in Turkey comprises both Caucasian and Oriental variants: roles of parental consanguinity and assortative mating. Hum Mutat 2003;21:552–553. 86. Uyguner O, Emiroglu M, Uzumcu A, et al. Frequencies of gap- and tightjunction mutations in Turkish families with autosomal-recessive nonsyndromic hearing loss. Clin Genet 2003;64:65–69. 87. Wu BL, Kenna M, Lip V, Irons M, Platt O. Use of a multiplex PCR/ sequencing strategy to detect both connexin 30 (GJB6) 342 kb deletion and connexin 26 (GJB2) mutations in cases of childhood deafness. Am J Med Genet A 2003;121A:102–108. 88. Azaiez H, Chamberlin GP, Fischer SM, et al. GJB2: the spectrum of deafness-causing allele variants and their phenotype. Hum Mutat 2004; 24:305–311. 89. Cryns K. A genotype-phenotype correlation for GJB2 (connexin 26) deafness. J Med Genet 2004;41:147–154. 90. Erbe CB, Harris KC, Runge-Samuelson CL, Flanary VA, Wackym PA. Connexin 26 and connexin 30 mutations in children with nonsyndromic hearing loss. Laryngoscope 2004;114:607–611. 91. Feldmann D, Denoyelle F, Chauvin P, et al. Large deletion of the GJB6 gene in deaf patients heterozygous for the GJB2 gene mutation: genotypic and phenotypic analysis. Am J Med Genet A 2004;127A:263–267. 92. Fitzgerald T, Duva S, Ostrer H, et al. The frequency of GJB2 and GJB6 mutations in the New York State newborn population: feasibility of genetic screening for hearing defects. Clin Genet 2004;65:338–342. 93. Gasmelseed NM, Schmidt M, Magzoub MM, et al. Low frequency of deafness-associated GJB2 variants in Kenya and Sudan and novel GJB2 variants. Hum Mutat 2004;23:206–207. 94. Gronskov K, Larsen LA, Rendtorff ND, Parving A, Norgaard-Pedersen B, Brondum-Nielsen K. GJB2 and GJB6 mutations in 165 Danish patients showing non-syndromic hearing impairment. Genet Test 2004;8:181–184. 95. Iliadou V, Eleftheriades N, Metaxas AS, et al. Audiological profile of the prevalent genetic form of childhood sensorineural hearing loss due to GJB2 mutations in northern Greece. Eur Arch Otorhinolaryngol 2004; 261:259–261. 96. Levi H, Tell L, Cohen T. Sensorineural hearing loss in Jewish children born in Jerusalem. Int J Pediatr Otorhinolaryngol 2004;68:1245–1250. 97. Lustig LR, Lin D, Venick H, et al. GJB2 gene mutations in cochlear implant recipients: prevalence and impact on outcome. Arch Otolaryngol Head Neck Surg 2004;130:541–546. 98. Mahdieh N, Nishimura C, Ali-Madadi K, et al. The frequency of GJB2 mutations and the Delta (GJB6-D13S1830) deletion as a cause of autosomal recessive non-syndromic deafness in the Kurdish population. Clin Genet 2004;65:506–508. 99. Mesolella M, Tranchino G, Nardone M, Motta S, Galli V. Connexin 26 mutations in nonsyndromic autosomal recessive hearing loss: speech and hearing rehabilitation. Int J Pediatr Otorhinolaryngol 2004;68:995– 1005. 100. Oliveira CA, Alexandrino F, Abe-Sandes K, et al. Frequency of the 35delG Mutation in the GJB2 Gene in Samples of European, Asian, and African Brazilians. Hum Biol 2004;76:313–316. 101. Belintani Piatto V, Maria Goloni Bertollo E, Lucia Sartorato E, Victor Maniglia J. Prevalence of the GJB2 mutations and the del(GJB6D13S1830) mutation in Brazilian patients with deafness. Hear Res 2004;196:87–93. 102. Roux AF, Pallares-Ruiz N, Vielle A, et al. Molecular epidemiology of DFNB1 deafness in France. BMC Med Genet 2004;5:5. Chan & Chang: Systematic Review of Cx-26-Associated Hearing Loss 103. Seeman P, Malikova M, Raskova D, et al. Spectrum and frequencies of mutations in the GJB2 (Cx26) gene among 156 Czech patients with prelingual deafness. Clin Genet 2004;66:152–157. 104. Shi GZ, Gong LX, Xu XH, Nie WY, Lin Q, Qi YS. GJB2 gene mutations in newborns with non-syndromic hearing impairment in Northern China. Hear Res 2004;197:19–23. 105. Sinnathuray AR, Toner JG, Clarke-Lyttle J, Geddis A, Patterson CC, Hughes AE. Connexin 26 (GJB2) gene-related deafness and speech intelligibility after cochlear implantation. Otol Neurotol 2004;25:935–942. 106. Toth T, Kupka S, Haack B, et al. GJB2 mutations in patients with nonsyndromic hearing loss from Northeastern Hungary. Hum Mutat 2004; 23:631–632. 107. Wattanasirichaigoon D, Limwongse C, Jariengprasert C, et al. High prevalence of V37I genetic variant in the connexin-26 (GJB2) gene among non-syndromic hearing-impaired and control Thai individuals. Clin Genet 2004;66:452–460. 108. Xiao ZA, Xie DH. GJB2 (Cx26) gene mutations in Chinese patients with congenital sensorineural deafness and a report of one novel mutation. Chin Med J (Engl) 2004;117:1797–1801. 109. Alvarez A, del Castillo I, Villamar M, et al. High prevalence of the W24X mutation in the gene encoding connexin-26 (GJB2) in Spanish Romani (gypsies) with autosomal recessive non-syndromic hearing loss. Am J Med Genet A 2005;137A:255–258. 110. Angeli SI, Yan D, Telischi F, et al. Etiologic diagnosis of sensorineural hearing loss in adults. Otolaryngol Head Neck Surg 2005;132:890–895. 111. Cheng X, Li L, Brashears S, et al. Connexin 26 variants and auditory neuropathy/dys-synchrony among children in schools for the deaf. Am J Med Genet A 2005;139:13–18. 112. Frei K, Ramsebner R, Lucas T, et al. GJB2 mutations in hearing impairment: identification of a broad clinical spectrum for improved genetic counseling. Laryngoscope 2005;115:461–465. 113. Hutchin T, Coy NN, Conlon H, et al. Assessment of the genetic causes of recessive childhood non-syndromic deafness in the UK - implications for genetic testing. Clin Genet 2005; 68:506–512. 114. Kalay E, Caylan R, Kremer H, de Brouwer AP, Karaguzel A. GJB2 mutations in Turkish patients with ARNSHL: prevalence and two novel mutations. Hear Res 2005;203:88–93. 115. Kunstmann E, Hildmann A, Lautermann J, Aletsee C, Epplen JT, Sudhoff H. Congenital hearing loss. Molecular genetic diagnosis of connexin genes and genetic counselling. HNO 2005;53:773–778. 116. Liu XZ, Pandya A, Angeli S, et al. Audiological features of GJB2 (connexin 26) deafness. Ear Hear 2005;26:361–369. 117. Marlin S, Feldmann D, Blons H, et al. GJB2 and GJB6 mutations: genotypic and phenotypic correlations in a large cohort of hearing-impaired patients. Arch Otolaryngol Head Neck Surg 2005;131:481–487. 118. Mercier G, Bathelier C, Lucotte G. Connexin 26 mutation 35delG: prevalence of carriers in various regions in France. Int J Pediatr Otorhinolaryngol 2005;69:1187–1190. 119. Minarik G, Ferakova E, Ficek A, Polakova H, Kadasi L. GJB2 gene mutations in Slovak hearing-impaired patients of Caucasian origin: spectrum, frequencies and SNP analysis. Clin Genet 2005;68:554–557. 120. Najmabadi H, Nishimura C, Kahrizi K, et al. GJB2 mutations: passage through Iran. Am J Med Genet A 2005;133A:132–137. 121. Oguchi T, Ohtsuka A, Hashimoto S, et al. Clinical features of patients with GJB2 (connexin 26) mutations: severity of hearing loss is correlated with genotypes and protein expression patterns. J Hum Genet 2005;50:76–83. 122. Piatto VB, Oliveira CA, Alexandrino F, Pimpinati CJ, Sartorato EL. Prospects for genetic hearing loss screening: 35delG mutation tracking in a newborn population. J Pediatr (Rio J) 2005;81:139–142. 123. Posukh O, Pallares-Ruiz N, Tadinova V, Osipova L, Claustres M, Roux AF. First molecular screening of deafness in the Altai Republic population. BMC Med Genet 2005;6:12. 124. Sansovic I, Knezevic J, Matijevic T, Balen S, Barisic I, Pavelic J. Prevalence of the 35delG mutation in the GJB2 gene of patients with nonsyndromic hearing loss from Croatia. Genet Test 2005;9:297–300. 125. Santos RL, Wajid M, Pham TL, et al. Low prevalence of Connexin 26 (GJB2) variants in Pakistani families with autosomal recessive nonsyndromic hearing impairment. Clin Genet 2005;67:61–68. 126. Santos RL, Aulchenko YS, Huygen PL, et al. Hearing impairment in Dutch patients with connexin 26 (GJB2) and connexin 30 (GJB6) mutations. Int J Pediatr Otorhinolaryngol 2005;69:165–174. 127. Snoeckx RL, Djelantik B, Van Laer L, Van de Heyning P, Van Camp G. GJB2 (connexin 26) mutations are not a major cause of hearing loss in the Indonesian population. Am J Med Genet A 2005;135:126–129. 128. Snoeckx RL, Hassan DM, Kamal NM, Van Den Bogaert K, Van Camp G. Mutation analysis of the GJB2 (connexin 26) gene in Egypt. Hum Mutat 2005;26:60–61. 129. Dahl HH, Tobin SE, Poulakis Z, et al. The contribution of GJB2 mutations to slight or mild hearing loss in Australian elementary school children. J Med Genet 2006;43:850–855. 130. Hismi BO, Yilmaz ST, Incesulu A, Tekin M. Effects of GJB2 genotypes on the audiological phenotype: variability is present for all genotypes. Int J Pediatr Otorhinolaryngol 2006;70:1687–1694. 131. Neocleous V, Aspris A, Shahpenterian V, et al. High frequency of 35delG GJB2 mutation and absence of del(GJB6-D13S1830) in Greek Cypriot patients with nonsyndromic hearing loss. Genet Test 2006;10:285–289. 132. Neocleous V, Portides G, Anastasiadou V, Phylactou LA. Determination of the carrier frequency of the common GJB2 (connexin-26) 35delG muta- Laryngoscope 124: February 2014 133. 134. 135. 136. 137. 138. 139. 140. 141. 142. 143. 144. 145. 146. 147. 148. 149. 150. 151. 152. 153. 154. 155. 156. 157. 158. 159. tion in the Greek Cypriot population. Int J Pediatr Otorhinolaryngol 2006;70:1473–1477. Propst EJ, Stockley TL, Gordon KA, Harrison RV, Papsin BC. Ethnicity and mutations in GJB2 (connexin 26) and GJB6 (connexin 30) in a multi-cultural Canadian paediatric Cochlear Implant Program. Int J Pediatr Otorhinolaryngol 2006;70:435–444. Propst EJ, Blaser S, Stockley TL, Harrison RV, Gordon KA, Papsin BC. Temporal bone imaging in GJB2 deafness. Laryngoscope 2006;116:2178– 2186. Tang HY, Fang P, Ward PA, et al. DNA sequence analysis of GJB2, encoding connexin 26: observations from a population of hearing impaired cases and variable carrier rates, complex genotypes, and ethnic stratification of alleles among controls. Am J Med Genet A 2006;140:2401– 2415. Wiley S, Choo D, Meinzen-Derr J, Hilbert L, Greinwald J. GJB2 mutations and additional disabilities in a pediatric cochlear implant population. Int J Pediatr Otorhinolaryngol 2006;70:493–500. Yaeger D, McCallum J, Lewis K, et al. Outcomes of clinical examination and genetic testing of 500 individuals with hearing loss evaluated through a genetics of hearing loss clinic. Am J Med Genet A 2006;140: 827–836. Abidi O, Boulouiz R, Nahili H, et al. GJB2 (connexin 26) gene mutations in Moroccan patients with autosomal recessive non-syndromic hearing loss and carrier frequency of the common GJB2–35delG mutation. Int J Pediatr Otorhinolaryngol 2007;71:1239–1245. Chaleshtori MH, Farrokhi E, Shahrani M, et al. High carrier frequency of the GJB2 mutation (35delG) in the north of Iran. Int J Pediatr Otorhinolaryngol 2007;71:863–867. Christiani TV, Alexandrino F, de Oliveira CA, et al. Molecular study in Brazilian cochlear implant recipients. Am J Med Genet A 2007;143A: 1580–1582. de Oliveira CA, Alexandrino F, Christiani TV, et al. Molecular genetics study of deafness in Brazil: 8-year experience. Am J Med Genet A 2007; 143A:1574–1579. Gravina LP, Foncuberta ME, Estrada RC, Barreiro C, Chertkoff L. Carrier frequency of the 35delG and A1555G deafness mutations in the Argentinean population. Impact on the newborn hearing screening. Int J Pediatr Otorhinolaryngol 2007;71:639–643. Lucotte G. High prevalences of carriers of the 35delG mutation of connexin 26 in the Mediterranean area. Int J Pediatr Otorhinolaryngol 2007;71:741–746. Niceta M, Fabiano C, Sammarco P, et al. Epidemiological study of nonsyndromic hearing loss in Sicilian newborns. Am J Med Genet A 2007; 143A:1666–1670. Ogawa H, Suzutani T, Baba Y, et al. Etiology of severe sensorineural hearing loss in children: independent impact of congenital cytomegalovirus infection and GJB2 mutations. J Infect Dis 2007;195:782–788. Oliveira CA, Pimpinati CJ, Alexandrino F, Magna LA, Maciel-Guerra AT, Sartorato EL. Allelic frequencies of the 35delG mutation of the GJB2 gene in different Brazilian regions. Genet Test 2007;11:1–3. Piatto VB, Moreira OA, Silva MA, Maniglia JV, Pereira MC, Sartorato EL. Correlation between audiometric data and the 35delG mutation in ten patients. Braz J Otorhinolaryngol 2007; 73:777–783. Pollak A, Skorka A, Mueller-Malesinska M, et al. M34T and V37I mutations in GJB2 associated hearing impairment: evidence for pathogenicity and reduced penetrance. Am J Med Genet A 2007;143A:2534–2543. Putcha GV, Bejjani BA, Bleoo S, et al. A multicenter study of the frequency and distribution of GJB2 and GJB6 mutations in a large North American cohort. Genet Med 2007;9:413–426. Ramsebner R, Volker R, Lucas T, et al. High incidence of GJB2 mutations during screening of newborns for hearing loss in Austria. Ear Hear 2007;28:298–301. Tekin M, Arici ZS. Genetic epidemiological studies of congenital/prelingual deafness in Turkey: population structure and mating type are major determinants of mutation identification. Am J Med Genet A 2007; 143A:1583–1591. Utrera R, Ridaura V, Rodriguez Y, et al. Detection of the 35delG/GJB2 and del(GJB6-D13S1830) mutations in Venezuelan patients with autosomal recessive nonsyndromic hearing loss. Genet Test 2007;11:347–352. Yang JJ, Huang SH, Chou KH, Liao PJ, Su CC, Li SY. Identification of mutations in members of the connexin gene family as a cause of nonsyndromic deafness in Taiwan. Audiol Neurootol 2007;12:198–208. Abidi O, Boulouiz R, Nahili H, et al. Carrier frequencies of mutations/ polymorphisms in the connexin 26 gene (GJB2) in the Moroccan population. Genet Test 2008;12:569–574. Angeli SI. Phenotype/genotype correlations in a DFNB1 cohort with ethnical diversity. Laryngoscope 2008;118:2014–2023. Bajaj Y, Sirimanna T, Albert DM, Qadir P, Jenkins L, Bitner-Glindzicz M. Spectrum of GJB2 mutations causing deafness in the British Bangladeshi population. Clin Otolaryngol 2008;33:313–318. Baysal E, Bayazit YA, Ceylaner S, et al. GJB2 and mitochondrial A1555G gene mutations in nonsyndromic profound hearing loss and carrier frequencies in healthy individuals. J Genet 2008;87:53–57. Guo YF, Liu XW, Guan J, et al. GJB2, SLC26A4 and mitochondrial DNA A1555G mutations in prelingual deafness in Northern Chinese subjects. Acta Otolaryngol 2008;128:297–303. Gurtler N, Egenter C, Bosch N, Plasilova M. Mutation analysis of the Cx26, Cx30, and Cx31 genes in autosomal recessive nonsyndromic hearing impairment. Acta Otolaryngol 2008;128:1056–1062. Chan & Chang: Systematic Review of Cx-26-Associated Hearing Loss E51 160. Han SH, Park HJ, Kang EJ, et al. Carrier frequency of GJB2 (connexin26) mutations causing inherited deafness in the Korean population. J Hum Genet 2008;53:1022–1028. 161. Lee KY, Choi SY, Bae JW, et al. Molecular analysis of the GJB2, GJB6 and SLC26A4 genes in Korean deafness patients. Int J Pediatr Otorhinolaryngol 2008;72:1301–1309. 162. Naghavi A, Nishimura C, Kahrizi K, et al. GJB2 mutations in Baluchi population. J Genet 2008;87:195–197. 163. Schimmenti LA, Martinez A, Telatar M, et al. Infant hearing loss and connexin testing in a diverse population. Genet Med 2008;10:517–524. 164. Ammar-Khodja F, Faugere V, Baux D, et al. Molecular screening of deafness in Algeria: high genetic heterogeneity involving DFNB1 and the Usher loci, DFNB2/USH1B, DFNB12/USH1D and DFNB23/USH1F. Eur J Med Genet 2009;52:174–179. 165. Batissoco AC, Abreu-Silva RS, Braga MC, et al. Prevalence of GJB2 (connexin-26) and GJB6 (connexin-30) mutations in a cohort of 300 Brazilian hearing-impaired individuals: implications for diagnosis and genetic counseling. Ear Hear 2009;30:1–7. 166. Belguith H, Tlili A, Dhouib H, et al. Mutation in gap and tight junctions in patients with non-syndromic hearing loss. Biochem Biophys Res Commun 2009;385:1–5. 167. Bhalla S, Sharma R, Khandelwal G, Panda NK, Khullar M. Low incidence of GJB2, GJB6 and mitochondrial DNA mutations in North Indian patients with non-syndromic hearing impairment. Biochem Biophys Res Commun 2009;385:445–448. 168. Bonyadi M, Esmaeili M, Abhari M, Lotfi A. Mutation analysis of familial GJB2-related deafness in Iranian Azeri Turkish patients. Genet Test Mol Biomarkers 2009;13:689–692. 169. Cama E, Melchionda S, Palladino T, et al. Hearing loss features in GJB2 biallelic mutations and GJB2/GJB6 digenic inheritance in a large Italian cohort. Int J Audiol 2009;48:12–17. 170. Chen D, Chen X, Cao K, et al. High prevalence of the connexin 26 (GJB2) mutation in Chinese cochlear implant recipients. ORL J Otorhinolaryngol Relat Spec 2009;71:212–215. 171. Dai P, Yu F, Han B, et al. GJB2 mutation spectrum in 2,063 Chinese patients with nonsyndromic hearing impairment. J Transl Med 2009;7: 26. 172. Galehdari H, Foroughmand AM, Soorki MN, Mohammadian G. Absence of mutations in GJB2 (Connexin-26) gene in an ethnic group of southwest Iran. Indian J Hum Genet 2009;15:9–12. 173. Hamid M, Karimipoor M, Chaleshtori MH, Akbari MT. A novel 355– 357delGAG mutation and frequency of connexin-26 (GJB2) mutations in Iranian patients. J Genet 2009;88:359–362. 174. Joseph AY, Rasool TJ. High frequency of connexin26 (GJB2) mutations associated with nonsyndromic hearing loss in the population of Kerala, India. Int J Pediatr Otorhinolaryngol 2009;73:437–443. 175. Lee KH, Larson DA, Shott G, et al. Audiologic and temporal bone imaging findings in patients with sensorineural hearing loss and GJB2 mutations. Laryngoscope 2009;119:554–558. 176. Padma G, Ramchander PV, Nandur UV, Padma T. GJB2 and GJB6 gene mutations found in Indian probands with congenital hearing impairment. J Genet 2009;88:267–272. 177. Picciotti PM, Pietrobono R, Neri G, et al. Correlation between GJB2 mutations and audiological deficits: personal experience. Eur Arch Otorhinolaryngol 2009;266:489–494. 178. Primignani P, Trotta L, Castorina P, et al. Analysis of the GJB2 and GJB6 genes in Italian patients with nonsyndromic hearing loss: frequencies, novel mutations, genotypes, and degree of hearing loss. Genet Test Mol Biomarkers 2009;13:209–217. 179. Sansovic I, Knezevic J, Musani V, Seeman P, Barisic I, Pavelic J. GJB2 mutations in patients with nonsyndromic hearing loss from Croatia. Genet Test Mol Biomarkers 2009;13:693–699. 180. Tamayo ML, Olarte M, Gelvez N, et al. Molecular studies in the GJB2 gene (Cx26) among a deaf population from Bogota, Colombia: results of a screening program. Int J Pediatr Otorhinolaryngol 2009;73:97–101. 181. Yuan Y, You Y, Huang D et al. Comprehensive molecular etiology analysis of nonsyndromic hearing impairment from typical areas in China. J Transl Med 2009;7:79. 182. Bartsch O, Vatter A, Zechner U, et al. GJB2 mutations and genotypephenotype correlation in 335 patients from germany with nonsyndromic sensorineural hearing loss: evidence for additional recessive mutations not detected by current methods. Audiol Neurootol 2010;15:375–382. 183. Chinetti V, Iossa S, Auletta G, et al. Screening for GJB2 and GJB6 gene mutations in patients from Campania region with sensorineural hearing loss. Int J Audiol 2010;49:326–331. 184. Chora JR, Matos TD, Martins JH, et al. DFNB1-associated deafness in Portuguese cochlear implant users: prevalence and impact on oral outcome. Int J Pediatr Otorhinolaryngol 2010;74:1135–1139. 185. Dalamon V, Lotersztein V, Beheran A, et al. GJB2 and GJB6 genes: molecular study and identification of novel GJB2 mutations in the hearing-impaired Argentinean population. Audiol Neurootol 2010;15: 194–202. 186. Dzhemileva LU, Barashkov NA, Posukh OL, et al. Carrier frequency of GJB2 gene mutations c.35delG, c.235delC and c.167delT among the populations of Eurasia. J Hum Genet 2010;55:749–754. 187. Gravina LP, Foncuberta ME, Prieto ME, Garrido J, Barreiro C, Chertkoff L. Prevalence of DFNB1 mutations in Argentinean children with nonsyndromic deafness. Report of a novel mutation in GJB2. Int J Pediatr Otorhinolaryngol 2010;74:250–254. Laryngoscope 124: February 2014 E52 188. Hochman JB, Stockley TL, Shipp D, Lin VY, Chen JM, Nedzelski JM. Prevalence of Connexin 26 (GJB2) and Pendred (SLC26A4) mutations in a population of adult cochlear implant candidates. Otol Neurotol 2010; 31:919–922. 189. Kenna MA, Feldman HA, Neault MW, et al. Audiologic phenotype and progression in GJB2 (Connexin 26) hearing loss. Arch Otolaryngol Head Neck Surg 2010;136:81–87. 190. Kim HJ, Park CH, Kim HJ, et al. Sequence variations and haplotypes of the gjb2 gene revealed by resequencing of 192 chromosomes from the general population in Korea. Clin Exp Otorhinolaryngol 2010;3:65–69. 191. Ma Y, Yang T, Li Y, et al. Genotype-phenotype correlation of two prevalent GJB2 mutations in Chinese newborn infants ascertained from the Universal Newborn Hearing Screening Program. Am J Med Genet A 2010;152A:2912–2915. 192. Nivoloni Kde A, da Silva-Costa SM, Pomilio MC, et al. Newborn hearing screening and Genet Test in 8974 Brazilian neonates. Int J Pediatr Otorhinolaryngol 2010;74:926–929. 193. Shan J, Chobot-Rodd J, Castellanos R, et al. GJB2 mutation spectrum in 209 hearing impaired individuals of predominantly Caribbean Hispanic and African descent. Int J Pediatr Otorhinolaryngol 2010;74:611–618. 194. Siem G, Fagerheim T, Jonsrud C, et al. Causes of hearing impairment in the Norwegian paediatric cochlear implant program. Int J Audiol 2010; 49:596–605. 195. Teek R, Kruustuk K, Zordania R, et al. Prevalence of c.35delG and p.M34T mutations in the GJB2 gene in Estonia. Int J Pediatr Otorhinolaryngol 2010;74:1007–1012. 196. Tekin M, Xia XJ, Erdenetungalag R, et al. GJB2 mutations in Mongolia: complex alleles, low frequency, and reduced fitness of the deaf. Ann Hum Genet 2010;74:155–164. 197. Tsukada K, Nishio S, Usami S. A large cohort study of GJB2 mutations in Japanese hearing loss patients. Clin Genet 2010;78:464–470. 198. Yang JJ, Wang WH, Lin YC, et al. Prospective variants screening of connexin genes in children with hearing impairment: genotype/phenotype correlation. Hum Genet 2010;128:303–313. 199. Al-Achkar W, Moassass F, Al-Halabi B, Al-Ablog A. Mutations of the Connexin 26 gene in families with non-syndromic hearing loss. Mol Med Rep 2011;4:331–335. 200. Chen G, He F, Fu S, Dong J. GJB2 and mitochondrial DNA 1555A>G mutations in students with hearing loss in the Hubei Province of China. Int J Pediatr Otorhinolaryngol 2011;75:1156–1159. 201. Chinetti V, Iossa S, Auletta G, et al. Mutational analysis for GJB2, GJB6, and GJB3 genes in Campania within a universal neonatal hearing screening programme. Int J Audiol 2011;50:866–870. 202. Cordeiro-Silva Mde F, Barbosa A, Santiago M, et al. Mutation analysis of GJB2 and GJB6 genes in Southeastern Brazilians with hereditary nonsyndromic deafness. Mol Biol Rep 2011;38:1309–1313. 203. Daneshi A, Hassanzadeh S, Emamdjomeh H, et al. Prevalence of GJB2associated deafness and outcomes of cochlear implantation in Iran. J Laryngol Otol 2011;125:455–459. 204. Hayashi C, Funayama M, Li Y, et al. Prevalence of GJB2 causing recessive profound non-syndromic deafness in Japanese children. Int J Pediatr Otorhinolaryngol 2011;75:211–214. 205. Imtiaz F, Taibah K, Ramzan K, et al. A comprehensive introduction to the genetic basis of non-syndromic hearing loss in the Saudi Arabian population. BMC Med Genet 2011;12:91. 206. Ji YB, Han DY, Lan L, et al. Molecular epidemiological analysis of mitochondrial DNA12SrRNA A1555G, GJB2, and SLC26A4 mutations in sporadic outpatients with nonsyndromic sensorineural hearing loss in China. Acta Otolaryngol 2011;131:124–129. 207. Kabahuma RI, Ouyang X, Du LL, et al. Absence of GJB2 gene mutations, the GJB6 deletion (GJB6-D13S1830) and four common mitochondrial mutations in nonsyndromic genetic hearing loss in a South African population. Int J Pediatr Otorhinolaryngol 2011 Mar 8. [Epub ahead of print]. 208. Kenna MA, Rehm HL, Frangulov A, Feldman HA, Robson CD. Temporal bone abnormalities in children with GJB2 mutations. Laryngoscope 2011;121:630–635. 209. Kim SY, Lee BY, Lim JH, et al. Determination of the carrier frequencies of selected GJB2 mutations in the Korean population. Int J Audiol 2011;50:694–698. 210. Lin JW, Chowdhury N, Mody A, et al. Comprehensive diagnostic battery for evaluating sensorineural hearing loss in children. Otol Neurotol 2011;32:259–264. 211. Lipan M, Ouyang X, Yan D, Angeli S, Du LL, Liu XZ. Clinical comparison of hearing-impaired patients with DFNB1 against heterozygote carriers of connexin 26 mutations. Laryngoscope 2011;121:811–814. 212. Nogueira C, Coutinho M, Pereira C, Tessa A, Santorelli FM, Vilarinho L. Molecular investigation of pediatric portuguese patients with sensorineural hearing loss. Genet Res Int 2011;2011:587602. 213. Trotta L, Iacona E, Primignani P, et al. GJB2 and MTRNR1 contributions in children with hearing impairment from Northern Cameroon. Int J Audiol 2011;50:133–138. 214. Wu CC, Hung CC, Lin SY, et al. Newborn genetic screening for hearing impairment: a preliminary study at a tertiary center. PLoS One 2011;6: e22314. 215. Yoong SY, Mavrogiannis LA, Wright J, et al. Low prevalence of DFNB1 (connexin 26) mutations in British Pakistani children with nonsyndromic sensorineural hearing loss. Arch Dis Child 2011;96:798–803. Chan & Chang: Systematic Review of Cx-26-Associated Hearing Loss 216. Motasaddi Zarandy M, Rohanizadegan M, Salmasian H, Nikzad N, Bazazzadegan N, Malekpour M. Clinical application of screening for GJB2 mutations before cochlear implantation in a heterogeneous population with high rate of autosomal recessive nonsyndromic hearing loss. Genet Res Int 2011;2011:787026. 217. Zhang J, Wang Z, Dai W, Zeng Y, Li H. GJB2 allele variants and the associated audiologic features identified in Chinese patients with less severe idiopathic hearing loss. Genet Test Mol Biomarkers 2011;15:313– 318. 218. Zhao FF, Ji YB, Wang DY, et al. Phenotype-genotype correlation in 295 Chinese deaf subjects with biallelic causative mutations in the GJB2 gene. Genet Test Mol Biomarkers 2011;15:619–625. 219. Battelino S, Repic Lampret B, Zargi M, Podkrajsek KT. Novel connexin 30 and connexin 26 mutational spectrum in patients with progressive sensorineural hearing loss. J Laryngol Otol 2012;126:763–769. 220. Bazazzadegan N, Nikzat N, Fattahi Z, et al. The spectrum of GJB2 mutations in the Iranian population with non-syndromic hearing loss—a twelve year study. Int J Pediatr Otorhinolaryngol 2012;76:1164–1174. 221. Danilenko N, Merkulava E, Siniauskaya M, et al. Spectrum of genetic changes in patients with non-syndromic hearing impairment and extremely high carrier frequency of 35delG GJB2 mutation in Belarus. PLoS One 2012;7:e36354. 222. Davarnia B, Babanejad M, Fattahi Z, et al. Spectrum of GJB2 (Cx26) gene mutations in Iranian Azeri patients with nonsyndromic autosomal recessive hearing loss. Int J Pediatr Otorhinolaryngol 2012;76:268–271. 223. Dodson KM, Georgolios A, Barr N, et al. Etiology of unilateral hearing loss in a national hereditary deafness repository. Am J Otolaryngol 2012;33:590–594. 224. Homoe P, Koch A, Rendtorff ND, et al. GJB2 (Connexin-26) mutations are not frequent among hearing impaired patients in east Greenland. Int J Audiol 2012;51:433–436. Laryngoscope 124: February 2014 225. Khalifa Alkowari M, Girotto G, Abdulhadi K, et al. GJB2 and GJB6 genes and the A1555G mitochondrial mutation are only minor causes of nonsyndromic hearing loss in the Qatari population. Int J Audiol 2012; 51:181–185. 226. King PJ, Ouyang X, Du L, Yan D, Angeli SI, Liu XZ. Etiologic diagnosis of nonsyndromic genetic hearing loss in adult vs pediatric populations. Otolaryngol Head Neck Surg 2012;147:932–936. 227. Minarik G, Tretinarova D, Szemes T, Kadasi L. Prevalence of DFNB1 mutations in Slovak patients with non-syndromic hearing loss. Int J Pediatr Otorhinolaryngol 2012;76:400–403. 228. Popova DP, Kaneva R, Varbanova S, Popov TM. Prevalence of GBJ2 mutations in patients with severe to profound congenital nonsyndromic sensorineural hearing loss in Bulgarian population. Eur Arch Otorhinolaryngol 2012;269:1589–1592. 229. Radulescu L, Martu C, Birkenhager R, Cozma S, Ungureanu L, Laszig R. Prevalence of mutations located at the dfnb1 locus in a population of cochlear implanted children in eastern Romania. Int J Pediatr Otorhinolaryngol 2012;76:90–94. 230. Shin JW, Lee SC, Lee HK, Park HJ. Genetic Screening of GJB2 and SLC26A4 in Korean Cochlear Implantees: Experience of Soree Ear Clinic. Clin Exp Otorhinolaryngol 2012;5(suppl 1):S10–13. 231. Usami S, Nishio SY, Nagano M, Abe S, Yamaguchi T. Simultaneous screening of multiple mutations by invader assay improves molecular diagnosis of hereditary hearing loss: a multicenter study. PLoS One 2012;7:e31276. 232. Yuan Y, Zhang X, Huang S, et al. Common molecular etiologies are rare in nonsyndromic Tibetan Chinese patients with hearing impairment. PLoS One 2012;7:e30720. 233. Zainal SA, Md Daud MK, Abd Rahman N, Zainuddin Z, Alwi Z. Mutation detection in GJB2 gene among Malays with non-syndromic hearing loss. Int J Pediatr Otorhinolaryngol 2012;76:1175–1179. Chan & Chang: Systematic Review of Cx-26-Associated Hearing Loss E53